Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AbCellera (NASDAQ: ABCL) Secures $28 1 Million Upfront in Vertex Collaboration

AbCellera (NASDAQ: ABCL) announced a collaboration with Vertex Pharmaceuticals that includes a $28 1 million upfront cash contribution. The deal also promises additional milestone payments and tiered royalties, expanding the company’s revenue potential.

Vinay Lochav | 30 July 2026

Agios Pharma's Mitapivat Performance Raises Investor Questions

Agios Pharma is on the verge of releasing earnings that could significantly influence its market trajectory, primarily due to the anticipated performance of its newly introduced drug, Mitapivat. Investors are keenly focused on how initial uptake and the overall reception of the drug will …

Vinay Lochav | 30 July 2026

Amarin (NASDAQ: AMRN) Reports Q2 Earnings: EPS Hits $0.04, Beats Expectations

Amarin Corporation’s (NASDAQ: AMRN) recent earnings report revealed a second quarter earnings per share (EPS) of $0.04, surpassing the estimated loss of $-0.01. The results, announced on July 29, 2026, reflect early success in Amarin's newly adopted international commercial strategy, particularly through its partnership …

Vinay Lochav | 30 July 2026

Bausch Health Companies (TSX: BHC) Achieves 13% Revenue Growth, Signals Strength

Bausch Health Companies Inc. delivered better-than-expected financial results for the second quarter, reporting an earnings per share (EPS) of $1.26, surpassing analyst estimates of $1.05. This solid performance comes alongside a notable revenue increase, with the company achieving consolidated revenues of $2.85 billion for …

Vinay Lochav | 30 July 2026

Centene Corp (NYSE: CNC) Redeems Portion of 2027 Senior Notes

Centene Corp (NYSE: CNC) executed a partial redemption of its 2027 senior notes, reducing the outstanding balance while maintaining a sizable portion of the issuance. The redemption was performed at a price that matches the full face value of the notes, ensuring investors receive …

Vinay Lochav | 30 July 2026

Dyne Therapeutics (NASDAQ: DYN) Reports Q2 Loss of $178.6M Amid Growth Initiatives

Dyne Therapeutics, Inc. recorded a net loss of $178.6 million for the second quarter of 2026, reflecting significant investment in clinical programs. The company's strategic focus on upcoming FDA approvals for its therapies positions it for future growth, crucial for investors focused on biotech …

Vinay Lochav | 30 July 2026

Viatris (NASDAQ:VTRS) Wins FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo

Viatris (NASDAQ:VTRS) has received FDA approval for Gwyn Lo, a once-weekly transdermal combined hormonal contraceptive patch delivering a low dose of estrogen, positioning the product as a discreet, non-invasive, and reversible option for women of childbearing potential. The patch is indicated for women with …

Nitish Kishor | 30 July 2026

Viking Therapeutics Slips Pre-Market Despite Earnings Beat as Cash Burn and Insider Sales Weigh on Sentiment

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares declined in pre-market trading despite reporting a smaller-than-expected second-quarter loss, as investors remained focused on the pace of the company's cash burn. Viking is a San Diego-based clinical-stage biopharmaceutical company developing novel, orally available therapies for metabolic and endocrine …

Nitish Kishor | 30 July 2026

Teladoc Health, Inc. (NYSE:TDOC) Plunges 20% Pre-Market Today on Weak Guidance and BetterHelp Decline

Teladoc Health, Inc. (NYSE:TDOC) shares plunged in pre-market trading after the company reported second-quarter results that missed revenue estimates and issued a sharply reduced full-year outlook. Teladoc is a New York-based global leader in virtual care, providing telehealth services to approximately 94 million members …

Nitish Kishor | 30 July 2026

Teleflex (NYSE:TFX) Wins FDA Approval for First-Ever Freeze Dried Plasma Product

Teleflex (NYSE:TFX) has received Biologics License Application approval from the FDA for EZPLAZ Freeze Dried Plasma, marking the first freeze dried plasma product ever licensed by the agency and the first biologics license for a blood component in the company's history. The product is …

Nitish Kishor | 30 July 2026
Support

Hi! How can we help you today?

Loading…